Abstract
The release of cytochrome c from the intermembrane space of mitochondria into the cytosol is one of the critical events in apoptotic cell death. In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor α (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase. Staurosporine-induced apoptosis is sensitive to Bcl-2 but insensitive to Cyclosporin A and oligomycin. The effect of oligomycin is not due to changes in mitochondrial membrane potential or to inhibition of ATP synthesis/hydrolysis since (a) uncouplers (CCCP, DNP) which discharge the membrane potential fail to abolish the protective action of oligomycin and (b) aurovertin B (another inhibitor of H+-ATP-synthase, affecting its F1 component) do not affect apoptosis. A role of oligomycin-sensitive F0 component of H+-ATP-synthase in the TNF-induced PTP opening and apoptosis is suggested.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics
Nature Communications Open Access 26 August 2019
-
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Advances in Therapy Open Access 20 April 2017
-
Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice
Nature Communications Open Access 11 March 2016
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout





Abbreviations
- ANT:
-
adenine nucleotide translocator
- CCCP:
-
carbonyl cyanide m-chlorophenylhydrazone
- CsA:
-
Cyclosporin A
- DCF:
-
dichlorofluorescine
- DCFDA:
-
dichlorofluorescine diacetate
- DMEM:
-
Dulbecco's modified Eagle's medium
- DNP:
-
2,4-p-dinitrophenol
- DOG:
-
2-deoxiglucose
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- PTP:
-
permeability transition pore
- Sts:
-
staurosporine
- TFP:
-
trifluoropyrasine
- TNF:
-
tumor necrosis factor α
References
Bradham CA, Qian T, Streetz K, Tratwein C, Brenner DA, Lemasters JJ . 1998 Mol. Cell. Biol. 18: 6353–6364
Broekemeier KM, Pfeiffer DR . 1995 Biochemistry 34: 16440–16449
Domnina LV, Ivanova OY, Chernyck BV, Skulachev VP, Vasiliev YM . 2002 Biochemistry (Moscow) 67: 737–746
Du C, Fang M, Li Y, Li L, Wang X . 2000 Cell 102: 33–42
Eguchi Y, Shimizu S, Tsujimoto Y . 1997 Cancer Res. 57: 1835–1840
Goldstein JC, Waterhouse NJ, Juin P, Evans GI, Green DR . 2000 Nature Cell. Biol. 2: 156–162
Hsu YT, Walter KG, Joule RJ . 1997 Proc. Natl. Acad. Sci. USA 94: 3668–3672
Ikemoto H, Tani E, Ozaki I, Kitagawa H, Arita N . 2000 Cell Death Diff. 7: 511–520
Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD . 1997 Science 275: 1132–1136
Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Shlesinger PH . 2000 Cell Death Diff. 7: 1166–1173
Kroemer G . 1997 Nature Med. 3: 614–620
Kroemer G, Dallaporta B, Reshe-Rigon M . 1998 Ann. Rev. Physiol. 60: 619–642
Kroemer G, Reed JC . 2000 Nature Med. 6: 513–519
Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P . 1997 J. Exp. Med. 185: 1481–1486
Li LY, Luo X, Wang X . 2001 Nature 412: 95–99
Liu Y, Peterson DA, Kimura H, Schubert D . 1997 J. Neurochem. 69: 581–593
Matsuyama S, Xu Q, Velours J, Reed JC . 1998 Mol. Cell 1: 327–336
Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y . 1998 Proc. Natl. Acad. Sci. USA 95: 14681–14686
Novgorodov SA, Gudz TI, Mohr Yu E, Goncharenko EN, Yaguzhinsky LS . 1989 FEBS Lett. 247: 255–258
Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S . 2002 Proc. Natl. Acad. Sci. USA 99: 1259–1263
Peachman KK, Lyles DS, Bass DA . 2001 Proc. Natl. Acad. Sci. USA 98: 1717–1722
Salomon AR, Voehringer DW, Herzenberg LA, Khosla C . 2000 Proc. Natl. Acad. Sci. USA 97: 14766–14771
Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S . 1999 EMBO J. 18: 2040–2048
Scorrano L, Ashiya M, Buttle K, Weiler S, Oakes SA, Mannella CA, Korsmeyer SJ . 2002 Dev. Cell 2: 55–67
Shchepina LA, Popova EN, Pletjushkina OYu, Chernyak BV . 2002 Biochemistry (Moscow) 67: 222–226
Sidoti-de Fraisse C, Rincheval V, Risler Y, Mignotte B, Vayssiere J-L . 1998 Oncogene 17: 1639–1651
Skulachev VP . 1996a FEBS Lett. 397: 7–10
Skulachev VP . 1996b Quart. Rev. Biophys. 29: 169–202
Skulachev VP . 1998 FEBS Lett. 423: 275–280
Skulachev VP . 1999 Mol. Asp. Med. 20: 139–184
Tafani M, Minchenko DA, Serroni A, Farber JL . 2001 Cancer Res. 61: 2459–2466
Tafani M, Schneider TG, Pastorino JG, Farber JL . 2000 Am. J. Physiol. 156: 2111–2121
Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB . 1997 Cell 91: 627–637
Verhagen AM, Ekert PG, Pakush M, Silke J, Connoly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL . 2000 Cell 102: 45–53
Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ . 2000 Genes Dev. 14: 2060–2071
Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ, Linnane AW . 1994 FEBS Lett. 339: 40–44
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng I-I, Jones DP, Wang X . 1997 Science 275: 1129–1132
Zhuang J, Dinsdale D, Cohen GM . 1998 Cell Death Diff. 5: 953–962
Acknowledgements
The authors wish to thank Professor YM Vasiliev for intellectual support and helpful discussions, Dr LV Domnina, Dr OY Ivanova and Ms N Korovkina for help in some experiments, Dr G Belov for cells lines, and Dr V Korobko for a sample of TNF. This work was supported by Ludwig Cancer Research Institute Grant ROB 0863 and by RFBR Grants No 00-04-48090, 01-04-06048; 99-04-49256, 00-15-97799, 01-04-48606.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shchepina, L., Pletjushkina, O., Avetisyan, A. et al. Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene 21, 8149–8157 (2002). https://doi.org/10.1038/sj.onc.1206053
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206053
Keywords
This article is cited by
-
F1Fo adenosine triphosphate (ATP) synthase is a potential drug target in non-communicable diseases
Molecular Biology Reports (2023)
-
Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target
Medical Oncology (2020)
-
Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics
Nature Communications (2019)
-
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Advances in Therapy (2017)
-
Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice
Nature Communications (2016)